“Increasing Prevalence of Ocular Diseases”
The main reason for the growth of the ophthalmology small molecule API market is the increasing prevalence of ocular diseases, particularly age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and dry eye disease. As the global population ages and with the rise in chronic conditions such as diabetes, the demand for effective and affordable treatments for these diseases is growing rapidly.
Small molecule drugs offer significant advantages, including lower cost compared to biologics, ease of administration, and wider accessibility, making them an attractive treatment option for both patients and healthcare systems, especially in regions with budget constraints. In addition, the development of novel small molecule therapies targeting specific pathways in the eye, such as Rho kinase inhibitors for glaucoma and tyrosine kinase inhibitors for diabetic retinopathy, is expanding the therapeutic options available, improving patient outcomes, and fueling market growth. These factors, combined with increasing healthcare access and awareness, particularly in emerging markets, are driving the demand and growth of the ophthalmology small molecule API ma
